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ABSTRACT
INTRODUCTION: Evidence for the effectiveness of drug treatment for depression in primary care 
settings remains limited, with little information on newer antidepressant classes.
AIM: To update an earlier Cochrane review on the effectiveness of antidepressants in  primary 
care to include newer antidepressant classes, and to examine the efficacy of individual 
agents.
METHODS: Selection criteria included antidepressant studies with a randomly assigned 
placebo group where half or more subjects were recruited from primary care. The Cochrane 
Collaboration Depression, Anxiety and Neurosis (CCDAN) group searched multiple databases 
to identify eligible studies. Data extraction was performed independently by two reviewers. 
Data were analysed using Revman version 5.3.5.
RESULTS: In total, 17 papers and 22 comparisons were included for analysis. Significant bene-
fits in terms of response were found for tricyclic antidepressants (TCA) with a relative risk (RR) 
= 1.23 (95% CI, 1.01–1.48), and serotonin selective reuptake inhibitors (SSRI) with a RR = 1.33 
(95% CI, 1.20–1.48). Mianserin was effective for continuous outcomes. Numbers needed to 
treat (NNT) for TCA = 8.5; SSRI = 6.5; and venlafaxine = 6. Most studies were industry-funded 
and of a brief duration (≤ 8 weeks). There was evidence of publication bias. There were no 
studies comparing newer antidepressants against placebo.
CONCLUSION: Antidepressants such as TCA, SSRI, SNRI (serotonin–norepinephrine reuptake 
inhibitor) and NaSSA (noradrenergic and specific serotonergic antidepressant) classes appear 
to be effective in primary care when compared with placebo. However, in view of the potential 
for publication bias and that only four studies were not funded by industry, caution is needed 
when considering their use in primary care.
KEYWORDS: Antidepressant agents; primary health care; placebos; clinical trial; meta-analysis; 
general practice
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Introduction
Depression is a leading cause for global dis-
ease burden. In many places around the world, 
depression is mainly managed in primary care 
settings where the prevalence of depressive 
disorders has been estimated to range from 10 
to 20%.1,2 Despite this, much of the evidence for 
the effectiveness of drug treatments used for 
depression have been based on studies conducted 
on patients treated in secondary and tertiary 
settings. Observational studies have found the 
naturalistic course of depressive disorders en-
countered in primary care tends to be less severe 
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and less complicated than those seen in specialist 
settings, with many primary care patients going 
into remission without treatment.3 As a result, 
there is ongoing debate about the effectiveness 
of antidepressant therapy for the management 
of primary care depression amid concerns that 
previous evidence may have been based on biased 
reporting or false-positive results.4,5 In summary, 
the evidence for benefit with antidepressants 
is mainly in cases of severe depression, and yet 
most depression in general practice is mild to 
moderate.
This current review was conducted primarily to 
update and extend an earlier Cochrane review 
on antidepressants use in primary care, which 
was limited to the evidence for the effectiveness 
of tricyclic (TCA) and selective serotonin 
reuptake inhibitors (SSRI) against placebo.6 As 
newer antidepressant drug classes have become 
available in recent years, this review update was 
conducted to allow a more complete review of 
current papers and to examine the effectiveness 
of specific agents within each drug class. Recent 
reviews have suggested that some drugs may be 
more effective than others, raising the possibility 
that the benefits of antidepressants may not 
necessarily be a class effect.7 Knowledge of the 
NNT for individual agents would be helpful in 
informing clinicians on antidepressant choice 
when managing depression in primary care 
settings. The aim of this study was to assess the 
effectiveness of all classes of antidepressants 
versus placebo in primary care patients.
Methods
Using a population, intervention, control and 
outcome (PICO) format, inclusion criteria for 
study selection were:
•	 Population. Primary care studies that exam-
ined the outcomes of antidepressant treatment 
of patients with depression where there was 
a placebo comparison group. ‘Primary care 
studies’ were defined as ≥ 50% of the study 
sample being subjects who have been recruited 
from primary care settings. ‘Patients with 
depression’ were defined as subjects diagnosed 
with depression by a primary care clini-
cian or by diagnostic inventory or criteria.
•	 Intervention. Any class of antidepres-
sant medication. The treating clinician 
could be from primary or secondary care, 
as we were interested in the drug/placebo 
difference and any non-drug skill would 
apply equally to all arms of the trials.
•	 Comparison. Placebo.
•	 Outcomes. Response or remission to treat-
ment for dichotomous outcomes, and the 
Hamilton Depression Rating Scale (HAM-
D) or the Montgomery Asberg Rating Scale 
(MADRS) for continuous outcomes. 
The search was conducted by the Cochrane Col-
laboration Depression, Anxiety and Neurosis 
(CCDAN) Group and included studies from the 
earlier Cochrane review and a CCDAN-Clinical 
Trials Registry update search (to examine re-
cords added to the registry from January 2007 to 
October 2015). The CCDAN search includes the 
databases of MEDLINE (1950–), EMBASE (1974–) 
and PsycINFO (1967–), and the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) 
to include review-specific searches of additional 
databases. Reports of trials were also sourced 
from international trial registers via the World 
WHAT GAP THIS FILLS
What is already known: Much of the evidence on drug treatment of 
depression has been based on studies conducted in secondary 
and tertiary settings where the spectrum and course of illness 
tends to be more severe and complicated than depression en-
countered in primary care, raising questions about the effective-
ness of antidepressants in patients being treated for depression 
in primary care settings. An earlier Cochrane review examined the 
effectiveness of TCA and SSRI in primary care settings and found 
both to be effective.
What this study adds: This study updates the Cochrane review by 
including newer antidepressant classes and calculating NNTs for 
individual drugs where data were available. There was evidence 
to support the effectiveness of TCAs and SSRIs when compared 
to placebo, and evidence of efficacy for SNRIs and NaSSA. NNT 
for TCA and SSRI classes and for specific agents (venlafaxine, 
amitriptyline, sertraline, escitalopram) were calculated. 
Publication bias and high levels of industry funding has also 
been reported and it is suggested that clinicians take this in to 
account when considering using antidepressant medication for 
depression in primary care.
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Health Organization’s trials portal (ICTRP), 
ClinicalTrials.gov, and drug companies. Finally, 
hand-searching of key journals, conference 
proceedings and other (non-Cochrane) system-
atic reviews and meta-analyses were performed. 
This search was updated in October 2015. Search 
terms used were for antidepressants versus 
placebo in primary care. The search is one page 
long, but in summary includes multiple terms 
for mood conditions (eg depression, dysthymia), 
generic names of all antidepressant medication, 
placebo, drug classes (eg SSRI, TCA, etc.) and 
primary care settings including general practice 
and ambulatory care. The search included all 
languages and references lists of papers were 
searched. We also wrote to authors of papers to 
see if they knew of any relevant papers we did 
not have. The final search was done in October 
2015 and the full search results are available 
from the authors. Three authors (BA, WM and 
SH) selected the studies from the abstracts. Full 
papers were obtained where there was disagree-
ment or uncertainty. Data were extracted from 
the selected papers in duplicate by two authors 
and recorded on a standardised data extraction 
form (Appendix 1). Data recorded included the 
PICO, funding sources, adverse events and those 
leading to withdrawal and the reviewer’s judge-
ment on risk of bias. The principal summary 
measure used was relative risk (RR) and effect 
sizes were translated into NNTs to enable easier 
interpretation by clinicians. We measured stand-
ard mean differences for continuous outcomes 
and RRs, and NNTs for dichotomous outcomes 
to ensure a significant finding on a continuous 
outcome was also significant on a dichotomous 
outcome. Where standard deviations (s.d.) were 
not reported, we used the highest value of s.d. 
from other studies in that class, including the 
highest s.d. for the active drug and the highest 
s.d. for the placebo. We also measured with-
drawal for any reason (WFAR) to quantify the 
dropout rates. The Cochrane RevMan software 
(version 5.3.5) was used to perform statistical 
analyses using a random effects model as the 
most conservative option. The PRISMA (Pre-
ferred Reporting Items for Systematic Reviews 
and Meta-Analyses) checklist (see Supplemen-
tary Material available at journal’s website) was 
followed.8
Results
The previous Cochrane review reported on 
15 papers.6 The literature search identified 151 
papers from 01 January 2007 to 31 December 
2013 (Figure 1). In addition, a search before 2007 
excluding known studies found five potential 
studies, none of which met the inclusion criteria. 
Two papers were removed because one was an 
abstract9 and the other was an early publication 
of the same study10 that was superseded by the 
full paper for the study.11 A paper from the earlier 
review was removed because the authors decided 
it did not meet the participant entry criteria.12
Two new papers came from the Linde (2015)13 
review.14,15 An additional search from 01 January 
2014 to 23 October 2015 found two additional 
studies.18,19 In summary, four new papers were 
found; one was excluded from our earlier review 
and a duplicate was removed. The final review 
included 17 papers with 10 TCA, nine SSRI, one 
venlafaxine and two mianserin comparisons 
with placebo.
Figure 1. Number of randomized trials (RCTs) found from the search strategy?????????????????????????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ??????????????????????????????? ?????????????????????????
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Table 1. Characteristics of randomised trials of antidepressants versus placebo by antidepressant class
Study year Diagnosis Age 
(years)












MDD & HAM-D 
17 ≥ 18
16–65 50 mg/day 
increasing to 
200 mg/day
63 GP 6 HAM-D 17 Yes
Blashki et al.26 Heterogeneous 
and women only
> 15 75 or 150 mg 82 GP and 
psychiatrist
4 HAM-D 17 Yes
Doogan and 
Langdon27 
MDD > 18 75 up to 150 
mg*
308 GP 6 MADRS and 
CGI
Yes
Hollyman et al.28 Heterogeneous 18–64 75 mg up to 
175 mg
141 Psychiatrist 6 HAM-D No





MDD 18–65 50–150 mg 91 1 Psychiatrist 
and 2 GPs
12 HAM-D ≤ 7 No†





Heterogeneous NR 75 mg 52 GP 4 HAM-D Yes
Thomson et al.21 Heterogeneous Median 33 75–150 mg 115 GP & 
Psychiatrist




MDD 18–70 Fluoxetine 115 ?Psychiatrist 4 Ham-D 21 Yes
Doogan and 
Langdon27
MDD > 18 Sertraline 
50–100 mg
308 GP 6 MADRS and 
CGI
Yes
Gastpar et al.15 MDD 18–70 Citalopram 
20 mg
257 GPs 4 HAM-D 17 Yes
Hergl et al.18 MDD > 18 Sertraline 
50–200 mg
166 Psychiatrist 10 HAM-D 17 Yes
Lepola et al.11 MDD 18–65 Escitalopram 





8 50% MADRS Yes
Malt et al.31 Heterogeneous Mean 48 Sertraline 
50–200 mg
372 GP 24 50% MADRS Yes
Wade et al.32 MDD 40/41 Escitalopram 
10 mg
380 Unclear 8 50% MADRs Yes
Venlafaxine SNRI




Brink33 Heterogeneous 18–65 30–60 mg 52 GP 4 HAMD 21 No
Malt et al.31 Heterogeneous Mean 48 30–120 mg 372 GP 24 50% MADRs Yes
* ‘Up to’ means starting at a lower dose and increasing up to the higher dose as needed.
† Company supplied drug and placebo but did not fund the study.
‘?Psychiatrist’ means not clear if this was done by a psychiatrist.
MDD, Major Depressive Disorder; HAM-D, Hamilton Depression Scale; MADRS, Montgomery Asberg depression rating scale; Heterogeneous, depression as 
diagnosed by a primary care clinician on a clinical basis alone; Moderate DD, moderate depressive disorder; NR, not reported; CGI, Clinical Global Impression; 
GP, general practitioner; SSRI, serotonin selective reuptake inhibitors; SNRI, serotonin–norepinephrine reuptake inhibitor; 50%, 50% reduction in the baseline 
score as a measure of response.
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Table 1 shows the characteristics of each of the 
studies by their drug class categories. Both TCAs 
and SSRIs were significantly effective compared 
with placebo for dichotomous scores of response/
remission (Figures 2 and 3). The RR for ben-
efit was 1.23 (95% CI, 1.01–1.48) for TCAs, and 
1.33 (95% CI, 1.20–1.48) for SSRIs. By using the 
pooled RR, the NNT for TCA (based on the me-
dian control event rate [MCER]) was 8.5, with a 
range of 7 to 16. The NNT for SSRI (based on the 
[MCER] was 6.5, with a range of 9 to 42. We are 
reporting a range of NNTs based on the range of 
control event rates, and it is not a confidence in-
terval. Results for continuous outcomes were also 
significant for the TCA standard mean difference 
(SMD) = –0.26 (95% CI, –0.5 to –0.02) and for 
the SSRI group SMD = –0.27 (95% CI, –0.38 to 
–0.16). For participants on low doses of TCAs 
(≤ 100 mg per day), the SMD was –0.27 (95% CI 
–0.38 to –0.16). A SMD of 0.5 is considered a 
moderate effect size, so that SMDs reported here 
would be small. For studies longer than 8 weeks, 
the results were not statistically significant for 
TCAs but they were for SSRIs. There was signifi-
cant heterogeneity for the TCA drugs (I2 = 77%) 
but not for the SSRI (I2 = 0).
There was limited but sufficient data to calculate 
the NNTs for some individual antidepressants 
(Table 2). This was possible for amitriptyline, ser-
traline, escitalopram and venlafaxine. We could 
not report a NNT for imipramine or citalopram, 
as their pooled estimate was significant on a 
fixed-effects analysis but not the random-effects 
analysis. There was insufficient data for dothiepin 
and paroxetine. We only had continuous data for 
mianserin, with a SMD of –0.37 (95% CI, –0.62 
to –0.13) for the two studies, so while statistically 
significant, did not allow a NNT to be calculated.
The median withdrawal rate for TCAs was 19% 
and 14% for the SSRIs. The WFAR was not 
Figure 2. Tricyclic antidepressants versus placebo with response/remission as the 
outcome
Figure 3. Serotonin selective reuptake inhibitors versus placebo with response/
remission as the outcome
Table 2. Effect size based on numbers needed to treat (NNT) using the pooled relative risk and the median value of the controlled event rates 
for each study
NNT calculated on the median control event rate Range
TCAs as a class 8.5 7–16
SSRIs as a class 6.5 6–42
TCA Amitriptyline (3 studies) 5 3–7
TCA Dothiepin (2 studies) Ns
TCA Imipramine (2 studies) Ns (fixed effects but not random effects) I2 = 44%
SSRI Sertraline (3 studies) 6 6–10
SSRI Escitalopram (2 studies) 8.5 8–9
SSRI Paroxetine (1 study) Ns one study only
SSRI Citalopram (2 study) Two studies (fixed effects but not random effects)
NaSSA Mianaserin (2 studies) Significant on continuous outcome Cannot calculate
SNRI Venlafaxine (1 study) 6 Single study
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statistically significant for either TCA or SSRI. In 
a post-hoc sensitivity analysis, where those who 
withdrew were considered to have not improved, 
the RRs for TCAs and SSRIs remained non-
significant.
Risk of bias
Most studies used a blinded active drug and pla-
cebo, but methods of randomisation or conceal-
ment were often not reported. Formal measures 
of bias would categorise most trials as having an 
unclear risk of bias; however, this may be unfair 
given most studies are old and the requirement 
for more rigid criteria for reporting have only 
been implemented in recent years. Of greater 
concern was industry involvement in 13 of the 17 
studies; funnel plots indicated there were some 
small studies with small effect sizes missing for 
both tricyclics and SSRIs (Appendix 2 and 3).
Discussion
Summary
Our results suggest antidepressants are effective 
when compared with placebo for depression in 
primary care. There were four broad medication 
groups, including TCA, SSRI, SNRI and NaSSA, 
and all had evidence of efficacy. This includes 
what we have called heterogeneous depression, 
which was usually described as patients with a 
primary care clinical diagnosis of depression. In 
other studies, it included a diagnosis by struc-
tured criteria such as the Diagnostic and Statisti-
cal Manual of Mental Disorders, 4th edition.17 
This was often augmented by a threshold from 
a depression inventory such as the Hamilton 
Depression Scale (mainly in the older papers), 
and the Montgomery Asberg Depression Rating 
Scale (in the more recent papers). The severity of 
depression and the effectiveness of antidepres-
sants is a contentious issue, owing to concern 
about publication bias. A meta-analysis of 35 
randomised controlled trials obtained from the 
Food and Drug Administration (which included 
unpublished data) found antidepressants were 
clearly effective only in patients with severe levels 
of depression (Hamilton Depression Rating Scale 
scores of ≥ 28).4 In this current review, the major-
ity of participants were in the mild-to-moderate 
level of severity. While we were able to pool data 
and show amitriptyline, sertraline and escit-
alopram were effective in two or more studies, 
caution is needed in suggesting that these medi-
cations should be chosen over others in their 
classes, given that the choice to study a particular 
medication is industry-driven.
Strengths and limitations
There were several strengths to this current 
review. It contains only studies conducted with 
patients recruited from primary care settings. All 
medications were compared with placebo and/
or with other medications where two medica-
tions were being studied. Authors were contacted 
to see if there were any relevant unpublished 
articles. This review contains two more papers 
than the 2015 review by Linde et al.13 and is the 
most comprehensive record of current papers.18,19 
A key limitation of the review is the high rate of 
withdrawal from the evaluated studies and the 
high level of industry involvement. The funnel 
plot suggests there are some missing small stud-
ies with smaller effects for both the TCA and the 
SSRIs. The funnel plot analyses were limited by 
the small number of studies in each class. High 
withdrawal rates observed in the studies is prob-
lematic, but mimics what happens in everyday 
clinical practice. Sensitivity analysis performed, 
assuming all withdrawals did not respond, did 
not materially change the effect measures. The 
types of adverse effects have been reported else-
where.6
Comparison with existing literature
There were notable absences of studies conducted 
in primary care on agents such as mirtazapine, 
bupropion and duloxetine, fluvoxamine, mil-
nacipran and reboxetine, all of which have been 
studied in secondary care settings. Our review 
reports data in 22 drug versus placebo combina-
tions. This is considerably less than a 30-year 
review of drug versus placebo studies, which 
included 121 comparisons.22 Their review in-
cluded 19 different medications, while our review 
included 11. There were 17 studies comparing 
fluoxetine versus placebo, while our review had 
only one. The most recent study of an antidepres-
sant versus placebo in primary care was in 2010,18 
ORIGINAL SCIENTIFIC PAPER
ORIGINAL RESEARCH: CLINICAL
VOLUME 8 • NUMBER 4 • DECEMBER 2016 J OURNAL OF PRIMARY HEALTH CARE 331
and, while the authors had disclosed involvement 
with pharmaceutical companies, the study did 
not seem to be industry-funded. The last medica-
tion versus medication study in primary care was 
published in 2012, and this was not funded by a 
pharmaceutical company.23 A recent network me-
ta-analysis looked at both placebo-controlled and 
other anti-depressant-controlled trials.13 While 
this included newer medications, all trials were 
drug-versus-drug comparisons, which we feel is 
important due to the controversy of efficacy in 
mild-to-moderate depression, which predomi-
nates in primary care. Another systematic review 
of anti-depressants found these medications were 
not effective for mild and sub-threshold depres-
sion.24 This finding reinforces our view there 
should be a placebo group at least in the short-
term.
Implications for practice
There appears to be some evidence to claim 
that antidepressants are effective for patients in 
primary care with depression. There was clear 
evidence for amitriptyline, mianserin, sertra-
line, escitalopram, venlafaxine, as individual 
drugs. There is almost certainly a commercial 
reason as to why particular medications were 
more studied, and the presence of evidence does 
not necessarily imply they are better than those 
with little or no evidence. Of more concern is the 
evidence of publication bias, as 13 of the 17 stud-
ies were funded by industry. We urge caution in 
their use. While antidepressant medications may 
be effective in primary care, our review does not 
answer the question of when they should be used, 
who should get them or how long primary care 
clinicians should wait to initiate prescribing.
Implications for research
There is an absence of evidence for the newer 
antidepressant medications versus placebo in pri-
mary care, many of which have been extensively 
studied in secondary care. This situation needs 
to be remedied. There also seems to be a trend 
towards medication-to-medication comparisons 
without a placebo arm, which may be problem-
atic, as there is a risk that two medications may 
appear similar in efficacy, but neither is better 
than placebo. This is important in primary care, 
as the range of depressive illnesses encountered 
are mainly in the mild-to-moderate spectrum 
where antidepressants are generally less effective. 
Research is needed, which is free from industry 
funding and of sufficient power and duration, to 
determine effectiveness over a longer timeframe.
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Appendix 1. Data extraction form
Variable Questions to consider Adequate? X/√/unclear
Methods Study design RCT of drug versus placebo 
Total study duration ……. months
Participants Setting
% recruited by GPs
% assessed by GPs
% intervention conducted by GPs




Who did the intervention?
Any drug company involvement?
Intervention Total number of intervention groups:
INTERVENTION
Specific intervention dose and dose escalation
PLACEBO
Specific intervention dose and dose escalation
Outcome and 
time 
Outcomes and time points
       1. Reported when – report only end-of-study 
outcomes
      2. What reported: CGI if no other
For each outcome of interest:
       1. Outcome definition, eg HAM-D, CGI, 
Montgomery Asberg
       2. Unit of measurement: dichotomous and/or 
continuous (if you have to estimate say so, eg ruler 
on a graph) 
Results        1. Number of participants allocated to each 
intervention group at baseline
       2. For each outcome of interest and at end of 
study
      3. Summary data for each intervention group
       4. Unit of measurement, eg HAM-D, Montgomery 
Asberg
      5. Serious events (number)
      6. Adverse effects number and type (number)
       7. Adverse effects leading to withdrawal (number)
      8. Withdrawal due to any reason (number)
Intention-to-treat 
analysis?
Was analysis performed in accordance with the 
principle of intention-to-treat?
Risk of bias (www.cochrane-handbook.org)
Domain Judgement 
Low risk, high risk, unclear risk
Support for judgement
Adequate random sequence generation?
Allocation concealment?
Blinding? (participants and personnel)




Overall assessment of risk of bias
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Appendix 2. Funnel plot for tricyclic antidepressants (TCA) versus placebo
Appendix 3. Funnel plot for tricyclic antidepressants (TCA) versus placebo
